Michael N Ruff

US Patent:

6713445, Mar 30, 2004

Filed:

Jun 12, 2001

Appl. No.:

09/647749

Inventors:

Candace Pert - Potomac MD
Michael Ruff - Potomac MD

Assignee:

Advanced Immuni T, Inc. - Stony Brook NY

International Classification:

A61K 3800

US Classification:

514 2, 530300, 530329, 530330, 514 4, 514 12

Abstract:

The HIV-1 envelope protein gp120 is toxic to rodent and human neurons by indirect mechanisms requiring accessory glial cells. Chemokines are known to block gp120 interactions with chemokine receptors on T cells, macrophanges, and microglia, thereby preventing viral infection. Gp120-induced neuronal killing in rat hippocampal cultures was partially or completely prevented by a specific short peptides related to chemokines, specially IKEYFTS (SEQ. ID NO: 2) and LESYT (SEQ. ID NO: 1). These peptides thus have use in the treatment of neurological degenerative diseases having symptoms associated with neuronal cell death.

US Patent:

7390788, Jun 24, 2008

Filed:

Jun 23, 2006

Appl. No.:

11/474049

Inventors:

Candace B. Pert - Potomac MD, US
Michael R. Ruff - Potomac MD, US

International Classification:

A61K 38/00
A61K 38/08
C07K 7/00

US Classification:

514 16, 514 2, 530300, 530328, 356319, 356322, 356326, 356324

Abstract:

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.

US Patent:

7700115, Apr 20, 2010

Filed:

Jun 23, 2006

Appl. No.:

11/426301

Inventors:

Michael Ruff - Potomac MD, US
Candace Pert - Potomac MD, US

Assignee:

Rapid Pharmaceuticals AG - Zug

International Classification:

A61K 39/12
A61K 39/21
A61K 39/00
A61K 45/00

US Classification:

4242081, 4241881, 4241921, 4242781

Abstract:

Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide sequences that are likely candidates for drugs which will offer effective treatment in such areas as Alzheimer's disease, psoriasis, multiple sclerosis and other diseases associated with the human inflammatory cascade as well as related retroviruses such as HTLV-1, the cause of tropical spastic paraparesis.

US Patent:

8178497, May 15, 2012

Filed:

Nov 14, 2007

Appl. No.:

11/940147

Inventors:

Michael Ruff - Potomac MD, US
Candace Pert - Potomac MD, US

Assignee:

Rapid Pharmaceuticals AG - Zug

International Classification:

A61K 38/08
A61K 38/00

US Classification:

514 217, 514 38

Abstract:

Residual HIV-1 replication reemerges after intensive therapy from location or locations in the body called the drug resistant non-plasma viral reservoir. Methods are disclosed of treating HIV by inhibiting or blocking this reemergence with various monomeric therapeutic peptide compositions including monomeric DAPTA prepared in least 80% trifluoroethanol, with vigorous shaking for at least about 24 hours at about 37 C.

US Patent:

20100184705, Jul 22, 2010

Filed:

Jan 16, 2010

Appl. No.:

12/688862

Inventors:

Michael Ruff - Potomac MD, US
Candace Pert - Potomac MD, US

International Classification:

A61K 38/08
C07K 7/06
A61P 29/00
A61P 25/28
A61P 17/06
A61P 19/02
C12Q 1/70

US Classification:

514 17, 530330, 435 5

Abstract:

Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide sequences that are likely candidates for drugs which will offer effective treatment in such areas as Alzheimer's disease, psoriasis, multiple sclerosis and other diseases associated with the human inflammatory cascade as well as related retroviruses such as HTLV-1, the cause of tropical spastic paraparesis.

US Patent:

20100216120, Aug 26, 2010

Filed:

Feb 23, 2010

Appl. No.:

12/711070

Inventors:

Candace Pert - Potomac MD, US
Michael Ruff - Potomac MD, US
Olivier Ducoudret - Kensington MD, US
Lokesh Agrawal - Germantown MD, US
Noel Baichoo - Catonsville MD, US

International Classification:

C12Q 1/70

US Classification:

435 5

Abstract:

An assay to detect or quantify HIV infectious virus from clinically relevant cellular compartments, or reservoirs, in anti-retrovirally treated patients whose viral levels are low to undetectable is described. The method detects infectious virus in patients whose plasma viral loads are considered to be below the limit of current PCR based detection methods and thereby is more relevant for guiding treatment. A further advantage is that the method allows viral tropism to be directly determined in the presence of specific inhibitors of CCR5 or CXCR4. Drug sensitivity can also be directly determined without the need to laboriously recover patient virus by culture for extended time periods, a method that allows for viral selection or evolution, which is not desirable. Patient cells, like the blood mononuclear cells, or monocytes, are isolated and cultured in the presence of cytokines like CSF-1/M-CSF or GM-CSF. to promote their differentiation. Cells are activated with lectins, mitogenic antibodies, phorbol esters, Toll Receptor stimulation or inducers of NfKb or NFAT, followed by agents that induce viral release, like ATP or stimulation of autophagy with LiCl, spermidine, or rapamycin. A key aspect of the invention relates to the timing of the addition of these agents for optimal viral release. A further aspect of the invention relates to sensitive detection of released virus which can be accomplished by adding so-called reporter cells which are under control of the HIV TAT protein so that upon infection these cells synthesize proteins or enzymes that allow for the measurement of infectious particles.

US Patent:

20110245180, Oct 6, 2011

Filed:

Feb 10, 2011

Appl. No.:

13/024324

Inventors:

Candace Pert - Potomac MD, US
Michael Ruff - Potomac MD, US

Assignee:

Rapid Pharmaceuticals, AG - Zug

International Classification:

A61K 38/02
A61P 25/28
A61P 27/02
A61P 25/00
A61P 25/16
A61P 35/00
A61P 29/00

US Classification:

514 178, 514 182, 514 179, 514 177, 514 193, 514 11

Abstract:

Chemokine signaling is important in neuropathic pain, with microglial cells expressing CCR2 playing a well established key role. DAPTA, a gp120-derived CCR5 entry-inhibitor has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation. We disclose here that as a stabilized analog of DAPTA, the short peptide All D TTNYT exhibits potent antagonism for both CCR2 (IC4.2 pM) and CCR5 (IC0.18 pM) in monocyte chemotaxis. Oral administration of All D TTNYT (0.05-1 mg/kg) for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia following partial ligation of the sciatic nerve in rats. Administered from day 8 to day 12, All D TTNYT (0.2-1 mg/kg) reverses already established hypersensitivity. All D TTNYT relieves pain hypersensitivity probably through either or both CCR2 and CCR5, since by using genetically deficient animals, we demonstrated that in addition to CCR2, CCR5 is also required for the development of neuropathic pain. Moreover, All D TTNYT is able to reduce spinal microglial activation, monocyte infiltration, and to inhibit inflammatory responses evoked by peripheral nerve injury that cause chronic pain. Our findings suggests that the targeting CCR2/CCR5 should provide greater efficacy than targeting CCR2 or CCR5 alone and dual CCR2/CCR5 antagonist All D TTNYT has the potential for broad clinical use in neuropathic pain treatment.

US Patent:

62425641, Jun 5, 2001

Filed:

Jun 15, 1992

Appl. No.:

7/898691

Inventors:

Candace B. Pert - Potomac MD
Michael R. Ruff - Potomac MD

International Classification:

A61K 3702

US Classification:

530328

Abstract:

Intranasal therapy using short peptides of the formula (I): R. sup. a -Ser-Thr-Thr-Thr-Asn-Tyr-R. sup. b (I) where R. sup. a represents an amino terminal residue Ala-, D-Ala or Cys-Ala- and R. sup. b represents a carboxy terminal residue -Thr, -Thr-amide, -Thr-Cys or -Thr-Cys-amide, or a derivative thereof, or a peptide of formula (II): R. sup. 1 -R. sup. 2 -R. sup. 3 -R. sup. 4 -R. sup. 5 (II) where R. sup. 1 is an amino terminal residue XR. sup. 6 or R. sup. 6 wherein R. sup. 6 is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu- and X is Cys, R. sup. 2 is Thr, Ser or Asp, R. sup. 3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp, R. sup. 4 is Tyr and R. sup. 5 is a carboxy terminal residue which is R. sup. 7 X or R. sup. 7 wherein R. sup.